A journal of molecular, cellular and biochemical toxicology
Guide for Authors
Chemico-Biological Interactions publishes research reports and review articles that
examine the molecular,
cellular, and/or biochemical basis of toxicologically relevant
outcomes. Special emphasis is placed on mechanisms associated with interactions
between chemicals and biological systems. Outcomes may include all traditional
endpoints caused by synthetic or naturally occurring chemicals,
both in vivo and in
vitro. Endpoints of interest include, but are not limited to, carcinogenesis, mutagenesis,
respiratory toxicology,
neurotoxicology, reproductive and developmental
toxicology, and immunotoxicology.
Abstracting Services
Biological Abstracts;
Elsevier BIOBASE/Current Awareness in Biological Sciences;
Chem. Abstracts; Current Contents/Life Sciences; Current Contents/Science
Cita-tion
Index; EMBASE/Excerpta Medica; Index Medicus; PASCAL M
Conflict of Interest Chemico-Biological Interactions
requires full disclosure of all potential conflicts of interest. At the end of the manuscript text (and in the cover letter of the manuscript),
under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people
or organisations that could inappropriately influence (bias) their work. If there are no conflicts of interest, the authors should state,
"The authors declare that there are no conflicts of interest." Signed copies of the Chemico-Biological Interactions Conflict
of Interest policy form are required upon submission. The Conflict of Interest policy form can be downloaded here.
In order to minimize delays, we strongly advise that the signed copies of these statements are prepared before you submit your manuscript.
The corresponding author is responsible for sharing this document with all co-authors. Each and every co-author must sign an individual
disclosure form. The corresponding author is responsible for uploading their form and those of their co-authors.
Submission of
Papers
Manuscripts are accepted for review with the understanding that the same work has not been published, that it is not under
consideration for publication elsewhere, and that its submission for publication has been approved by all of the authors and by the institution
where the work was carried out. Further, it is understood that any person cited as a source of personal communications has approved such
citation.
It is a condition of publication that all manuscripts must be submitted in English to Chemico-Biological Interactions
submission and review website http://ees.elsevier.com/chembioint. Authors are requested to transmit the text and art of
the manuscript in electronic form to this address. Each manuscript must also be accompanied by a cover letter outlining the basic findings
of the paper and their significance. Minimal exceptions will be exercised. The Editor welcomes submissions by the authors of the names
and addresses of up to five individuals who could expertly review the paper, and who are not from the same institutions as the authors.
The Editor reserves the right to use these or other reviewers. Should you be unable to provide an electronic version, please contact
the editorial office prior to submission at e-mail: toxcon@earthlink.net
It is understood that with submission of
this article the authors have complied with the institutional policies governing the humane and ethical treatment of the experimental
subjects, and that they are willing to share the original data and materials if so requested.
Types of papers Chemico-Biological
Interaction will publish ,(1) Papers reporting results of original
mechanistic research; (2) Review articles; (3) Letters to the
Editor; (4) Announcements
and advertisements. Review Articles - Outlines of papers for these sections should be submitted
to the
Editor in Chief. Announcements and Advertisements - Organisers of relevant meetings may submit
announcements through
the Editor-in-Chief for publication free of charge as space
permits. Advertising rates can be obtained upon request.
English language
help service
Upon request, Elsevier will direct authors to an agent who can check and improve the English of their paper (before
submission). Please contact authorsupport@elsevier.com for further information.
Abstract and Key words
An abstract of approx. 200-300 words is mandatory. A list of 3-6 key words,
which conveys the meaning of the paper as a whole, necessary
for correct
indexing and subsequent retrieval, must be submitted with the manuscript also. In
the event that key words are not supplied
editorial discretion will be exercised in
introducing appropriate words.
Figures
Each Figure should be in one of the following
preferred formats: Tiff, JPEG, PDF, and EPS. Please refer to http://www.elsevier.com/artworkinstructions
for detailed instructions
on preparing electronic artwork.
Tables
Tables should bear a short, descriptive title and should also be typed on separate
pages.
References
All references should be given at the end pf the paper. The numbering of the
references should be in
order of citation in the text, not in alphabetical order.
References must be complete, including initials of authors(s), full title of
the
paper, volume number, year of publication and first and last page numbers. Titles
of journals should be abbreviated in conformity
with the International Series
Catalogue, 1978. For citations of books, the following uniform sequence should
be maintained: Authors(s),
chapter title, in: editor(s) (if applicable), complete
book title, publisher, place of publication, year of publication, page numbers.
Please see below for relevant examples:
For a paper in a journal:
[l] M.E. Gore, E. Fryatt, E. Wiltshaw, T. Dawson, B.A. Robinson,
A.H. Calvert,
Cisplatin/carboplatin cross-resistance in ovarian cancer, Br. J. Cancer 60 (1989)
767-769.
For a paper in a contributed
volume or edited book:
[2] L.R. Kelland, Platinum complexes, in: B.A. Teicher (Ed.), Cancer Therapeutics,
Experimental and Clinical
Agents, Humana, Totowa, NJ, 1997. pp. 93-l12.
For a supplement to a journal:
G.R. Granneman, A.R. Braeckman, C.S. Locke, J.H.
Cavanaugh, L.M. Dube,
W.M. Awni, Effect of zileuton on theophylline pharmacokinetics, Clin. Pharma-cokinet.
2(Suppl. 29)(1995) 577-583.
All references cited in the text must be represented in the list of references and,
conversely all items in the list of references be
cited in the text. The citation for this
journal is Chem.-Biol. Interact.
Proofs
One set of page proofs in PDF
format will be sent by e-mail to the corresponding Author (if we do not have an e-mail address then paper proofs will be sent by post).
Elsevier now sends PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 available free from http://www.adobe.com/products/acrobat/readstep2.html
Instructions on how to annotate PDF files will accompany the proofs.
If you do not wish to use the PDF annotations function, you
may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting
line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query
Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post.
Please use this proof only for checking
the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted
for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article
published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication:
please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your
responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.
US National Institutes
of Health (NIH) voluntary posting (" Public Access") policy
Elsevier facilitates author response to the NIH voluntary posting
request (referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm) by posting
the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication. Upon
notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com ) that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award
number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript
that will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded
fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting
is prohibited.
Further Information
All questions arising after acceptance of the manuscript, especially those relating
to
proofs, should be directed to: Elsevier Ireland Ltd., Elsevier House,
Brookvale Plaze, East Park, Shannon, Co. Clare, Ireland. Tel.:
(+353-61) 709639;
Fax.: (+353-61) 709111.
Author Enquiries
For enquiries relating to the submission of articles (including
electronic submission where available), please visit the Author Gateway from Elsevier Science at http://authors.elsevier.com. The Author
Gateway also provides the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has
changed, as well as detailed artwork guidelines, copyright information, frequently asked questions and more.
E-Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail or, alternatively, option list 25 free
paper offprints. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image
and a disclaimer outlining the terms and conditions of use.
Advertising Information
Advertising orders and enquiries can
be sent to: Europe and ROW: Rachel
Leveson-Gower, Elsevier Ltd., Advertising Department, The Boulevard,
Langford Lane, Kidlington,
Oxford OX5 IGB, UK; Tel: (+44)(1865)843565;
Fax: (+44)(1865)843976; E-mail: r.leveson-gower@elsevier.co.uk. USA and
Canada: Elsevier Inc., M. Tino DeCarlo, 655 Avenue of the Americas, New
York, NY 10010-5107, USA; Tel: (+ 1)(212)633 3815; Fax: (+
1)(212)633 3820;
E-mail: t.decarlo@elsevier.com. Japan: Elsevier K.K., Advertising Depart-ment,
9-15 Higashi-Azabu
l-chome, Minato-ku, Tokyo 1060044, Japan; Tel:
(+81)(3)5561-5033; Fax: (+81)(3)5561-5047.
